The application relates to a thromboxane A2 (TXA2) inhibitor. The application also relates to an Antigen Presenting Cell (APC), in the cytosol of which said TXA2 inhibitor is contained. Said TXA2 inhibitor can e.g., be a Non-Steroidal Anti-Inflammatory Drug (NSAID).More particularly, the application relates to means, such as preparations, compositions, and methods, which comprise or involve said TXA2 inhibitor or APC.Said TXA2 inhibitor or APC can notably be used as stimulator or inducer of the immune response, more particularly of MHC Class I cross-presentation.
